Potent inhibition of TGF-βsignaling pathway regulator Abl: potential therapeutics for hepatic fibrosis

Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor

(2013) Dahlia R. Weiss et al.   ACS Chemical Biology

Rational Design of Angiotensin-I-Converting Enzyme Inhibitory Peptides by Integrating in silico Modeling and an in vitro Assay

(2013) Tao Jing et al.   ChemMedChem

Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design

(2013) P. Zhou et al.   CURRENT MEDICINAL CHEMISTRY

Specific Noncovalent Interactions at Protein-Ligand Interface: Implications for Rational Drug Design

(2012) P. Zhou et al.   CURRENT MEDICINAL CHEMISTRY

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib

(2011) Yuqing Liu et al.   JOURNAL OF HEPATOLOGY

Rapid Context-Dependent Ligand Desolvation in Molecular Docking

(2010) Michael M. Mysinger et al.   Journal of Chemical Information and Modeling

Scoring functions and their evaluation methods for protein–ligand docking: recent advances and future directions

(2010) Sheng-You Huang et al.   PHYSICAL CHEMISTRY CHEMICAL PHYSICS

Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies

(2009) J H W Distler et al.   ANNALS OF THE RHEUMATIC DISEASES

Hepatic fibrosis

(2009) Jingjing Jiao et al.   CURRENT OPINION IN GASTROENTEROLOGY

Fluorine Bonding — How Does It Work In Protein−Ligand Interactions?

(2009) Peng Zhou et al.   Journal of Chemical Information and Modeling

Predicting drug resistance of the HIV-1 protease using molecular interaction energy components

(2008) Tingjun Hou et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis

(2008) J. H. W. Distler et al.   RHEUMATOLOGY